Latest News

The growth hormone secretagogue receptor type 1a (GHS-R1a) is a Class A, rhodopsin-like G Protein Coupled Receptor (GPCR) that is expressed in a variety of human tissues and is differentially expressed in benign and malignant prostate cancer. Previously the peptidomimetic [Lys5(4-fluorobenzoyl-4-FB)]G7039 was designed as a molecular imaging tool for positron emission tomography (PET). However, this […]

Recent reports warn against erroneous mistaking of celiac and stellate sympathetic ganglia for metastatic lymph nodes on multimodal prostate-specific membrane antigen (PSMA)-ligand PET imaging. The aim was to check the intensity of Ga-PSMA-11 uptake and magnetic resonance (MR) features of superior cervical ganglia (SCG) on PET/MR imaging. In 89 patients 106 SCG were reliably identified […]

Significant morbidity is associated with overtreatment of clinically localized prostate cancer (PCa). Risk stratification tools such as novel biomarkers, MRI and risk calculators are useful in predicting which patients would benefit from active surveillance. This review examines current risk stratification tools in localized PCa and the safety of active surveillance in these patients. Very low […]

The use of lymph node density (LND) as a predictor of survival outcomes has been studied with urothelial carcinoma of the bladder. Similar results can be postulated to upper tract urothelial carcinoma (UTUC). This study aims to determine the overall survival of patients with lymph node positive UTUC based on LND, utilizing the National Cancer […]

Bladder cancer (BCa) can be divided into muscle-invasive BCa (MIBC) and non-muscle-invasive BCa (NMIBC). Whether the tumor infiltrates the detrusor muscle is a critical determinant of disease management in patients with BCa. However, the current preoperative diagnostic accuracy of muscular invasiveness is less than satisfactory. The authors report a radiomic-clinical nomogram for the individualized preoperative […]

Small cell carcinoma of the urinary tract is an aggressive malignancy that comprises less than 1% of urinary bladder cancers. The renal pelvis and ureter, also lined by urothelium, are rare sites for small cell carcinoma. The diagnosis and staging of upper tract cancer are difficult due to the need for small, atraumatic instrument to […]

Basel, Switzerland (UroToday.com) Dr. Matthew R. Smith provided a summary detailing the best use of osteoclast-targeted therapy for patients with bone mCRPC. Dr. Smith noted that it is important to distinguish between skeletal-related events and fragility fractures secondary to osteoporosis. Fragility fractures are possible in all men, at the site of normal bone, and have an […]